Le Lézard
Classified in: Health, Science and technology
Subject: CALENDAR OF EVENTS

Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call


Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call

SAN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that Apricus' third quarter 2017 financial results will be released on Thursday, November 2, 2017 at 4:01 p.m. Eastern Time.  Company management will host a conference call on Thursday, November 2, 2017, at 4:30 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International).  The conference ID number is 8498419.  The live audio webcast can be accessed via the Investor Relations' section of Apricus' website at www.apricusbio.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived webcast will remain available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud's phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit http://www.apricusbio.com.

Vitarostm is Apricus' trademark in the United States, which is pending registration and subject to the agreement with Allergan.  Vitaros® is a registered trademark of Ferring International Center S.A. in certain countries outside of the United States.  RayVatm is Apricus' trademark, which is registered in certain countries throughout the world and pending registration in the United States.

CONTACT:   
Matthew Beck
[email protected]
The Trout Group
(646) 378-2933


These press releases may also interest you

4 mai 2024
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
U.S.-based Iozera announces MOU with Government of Morocco for Launch of Eco-Friendly AI Data Center in Morocco
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...

4 mai 2024
Flash News: OK Wallet Now Integrated with JUICE, a Permissionless DeFi Protocol Built on the Blast Ecosystem's Layer 2 Infrastructure
OKX, a leading Web3 technology company, has issued updates for May 3, 2024. OKX today announced that its Web3 Wallet is now...

4 mai 2024
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Quick understanding of JA Solar's 2023 annual report
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...

4 mai 2024
Sogolytics Highlights AI-Powered Updates at UNLEASH America
Leading research and experience management firm Sogolytics will showcase innovations in HR and employee experience at UNLEASH America next week. "With such a rapid evolution in the world of HR tech, we're seeing some major changes in how employers...

More news about Science and technology...


News published on and distributed by: